Non-pegylated and Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma and the Risk of Severe Ocular Side-effects
DOI:
https://doi.org/10.2340/actadv.v102.2487Keywords:
cutaneous T-cell lymphoma, pegylated interferon alfa-2a, interferon alfa-2a, drug-related side effects, vision disorderAbstract
Abstract is missing (Short communication)
Downloads
References
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375-2390.
https://doi.org/10.1182/blood-2016-01-643569 DOI: https://doi.org/10.1182/blood-2016-01-643569
Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-484.
https://doi.org/10.1182/blood-2006-10-054601 DOI: https://doi.org/10.1182/blood-2006-10-054601
Dobos G, Pohrt A, Ram-Wolff C, Lebbe C, Bouaziz JD, Battistella M, et al. Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients. Cancers (Basel) 2020; 12: 2921.
https://doi.org/10.3390/cancers12102921 DOI: https://doi.org/10.3390/cancers12102921
Pulitzer M. Cutaneous T-cell lymphoma. Clin Lab Med 2017; 37: 527-546.
https://doi.org/10.1016/j.cll.2017.06.006 DOI: https://doi.org/10.1016/j.cll.2017.06.006
Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, et al. S2k guidelines - cutaneous lymphomas update 2016 - Part 1: classification and diagnosis (ICD10 C82 - C86). J Dtsch Dermatol Ges 2017; 15: 1266-1273.
https://doi.org/10.1111/ddg.13372 DOI: https://doi.org/10.1111/ddg.13372
Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, et al. S2k guidelines - cutaneous lymphomas update 2016 - Part 2: treatment and follow-up (ICD10 C82 - C86). J Dtsch Dermatol Ges 2018; 16: 112-122.
https://doi.org/10.1111/ddg.13401 DOI: https://doi.org/10.1111/ddg.13401
Schiller M, Tsianakas A, Sterry W, Dummer R, Hinke A, Nashan D, et al. Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol 2017; 31: 1841-1847.
https://doi.org/10.1111/jdv.14366 DOI: https://doi.org/10.1111/jdv.14366
Husken AC, Tsianakas A, Hensen P, Nashan D, Loquai C, Beissert S, et al. Comparison of pegylated interferon alpha-2b plus psoralen PUVA versus standard interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol 2012; 26: 71-78.
https://doi.org/10.1111/j.1468-3083.2011.04011.x DOI: https://doi.org/10.1111/j.1468-3083.2011.04011.x
Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40: 539-551.
https://doi.org/10.2165/00003088-200140070-00005 DOI: https://doi.org/10.2165/00003088-200140070-00005
Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003; 23: 23-28.
https://doi.org/10.1055/s-2003-41631 DOI: https://doi.org/10.1055/s-2003-41631
Callizo J, Feltgen N, Pantenburg S, Wolf A, Neubauer AS, Jurklies B, et al. Cardiovascular risk factors in central retinal artery occlusion: results of a prospective and standardized medical examination. Ophthalmology 2015; 122: 1881-1888.
https://doi.org/10.1016/j.ophtha.2015.05.044 DOI: https://doi.org/10.1016/j.ophtha.2015.05.044
Rentiya ZS, Wells M, Bae J, Chen KJ, Chao AN, Turgeon N, et al. Interferon-alpha-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations. Graefes Arch Clin Exp Ophthalmol 2019; 257: 447-452.
https://doi.org/10.1007/s00417-018-04209-7 DOI: https://doi.org/10.1007/s00417-018-04209-7
d'Alteroche L, Majzoub S, Lecuyer AI, Delplace MP, Bacq Y. Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis. J Hepatol 2006; 44: 56-61.
https://doi.org/10.1016/j.jhep.2005.07.026 DOI: https://doi.org/10.1016/j.jhep.2005.07.026
Kunkler AL, Binkley EM, Mantopoulos D, Hendershot AJ, Ohr MP, Kendra KL, et al. Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics. Graefes Arch Clin Exp Ophthalmol 2019; 257: 1771-1781.
https://doi.org/10.1007/s00417-019-04337-8 DOI: https://doi.org/10.1007/s00417-019-04337-8
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Jana D. Albrecht, Nadia Ninosu, Denise Barry, Thomas Albrecht, Marthe-Lisa Schaarschmidt, Sergij Goerdt, Jan P. Nicolay
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
